Merck Arcoxia 6,000-Patient Trial Will Study GI, Cardiac Events

Merck will conduct a 6,000-patient study of Arcoxia focusing on patient discontinuations due to gastrointestinal adverse events

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet